ARVINAS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ARVINAS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $262.60M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $263.40M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $78.50M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $131.40M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $53.60M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $25.90M | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $4.89M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $30.05M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $4.02M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $4.02M | Mar 16, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $46.70M | Feb 28, 2022 |
| FY2020 | Dec 31, 2020 | $21.80M | Mar 1, 2021 |
| FY2019 | Dec 31, 2019 | $18.30M | Mar 16, 2020 |
| FY2018 | Dec 31, 2018 | $14.30M | Mar 26, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($80.80M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($198.90M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($367.30M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($282.50M) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | ($191.00M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($119.30M) | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | ($21.05M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($17.68M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($17.16M) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($14.40M) | Mar 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($118.50M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($250.20M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($401.50M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($263.20M) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | ($188.40M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($120.80M) | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | ($22.79M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $5.50M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($18.42M) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($15.81M) | Mar 16, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $285.20M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $348.20M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $379.70M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $315.00M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $180.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $108.40M | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $20.41M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $16.59M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $16.00M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $14.19M | Mar 16, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($273.80M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($259.30M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($347.80M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($273.50M) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $559.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($89.70M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($40.60M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($16.12M) | Mar 1, 2021 |
| FY2018 | Dec 31, 2017 | $5.11M | Mar 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.90M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.80M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $2.90M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $6.80M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $4.70M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $6.40M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $6.30M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $2.83M | Mar 1, 2021 |
| FY2018 | Dec 31, 2017 | $1.01M | Mar 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $717.90M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.09B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.30B | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $1.27B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.58B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $717.40M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $301.64M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $199.28M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $66.85M | Mar 26, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $284.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $529.70M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $644.60M | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $703.90M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $799.90M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $75.20M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $74.96M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $62.61M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $66.60M | Mar 26, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $433.90M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $561.70M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $660.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $564.90M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $781.70M | Feb 11, 2025 |
| FY2023 | Dec 31, 2020 | $642.20M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $226.60M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $136.60M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | ($61.23M) | Mar 1, 2021 |
| FY2018 | Dec 31, 2016 | ($32.88M) | Mar 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.61B) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($1.53B) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($1.33B) | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | ($965.40M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($682.90M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($491.90M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($372.56M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($302.26M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($62.42M) | Mar 26, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.90M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $100.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $311.70M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $81.30M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $108.30M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $588.40M | Feb 23, 2023 |
| FY2020 | Dec 31, 2019 | $9.21M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $3.19M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $30.91M | Mar 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $600.0K | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $800.0K | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.00M | Feb 11, 2025 |
| FY2022 | Dec 31, 2022 | $1.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2021 | $1.00M | Feb 28, 2022 |
| FY2020 | Dec 31, 2020 | $2.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2019 | $2.00M | Mar 16, 2020 |
| FY2018 | Dec 31, 2018 | $2.17M | Mar 26, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (6) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (5) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Feb 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (6) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (5) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Feb 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 63.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 68.80M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 68.00M | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | 53.20M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 53.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 48.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 38.46M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 31.24M | Mar 16, 2020 |